(0)

Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

KFC Hall

Jan 29, 2015 9:30 AM - Jan 30, 2015 5:15 PM

1-6-1 Yokoami, Sumida-ku, Tokyo, 130-0015 Japan

18th Annual Workshop in Japan for Clinical Data Management

Back to Agendas

Session 1 : Which Data Should Be Collected in Clinical Trials?

Session Chair(s)

Keisuke Utsumi

Keisuke Utsumi

Head, Development Global Medical, Japan Development Division

GlaxoSmithKline K.K., Japan

Mika Ogasawara

Mika Ogasawara

Data Quality Lead, Biometrics and Data Management

Pfizer R&D Japan G.K., Japan

What Are Valuable Data for the clinical Evaluation of Novel Drugs? - From the regulator's view point -

Speaker(s)

Tetsuo Nakabayashi, MD, PhD

What Are Valuable Data for the clinical Evaluation of Novel Drugs? - From the regulator's view point -

Tetsuo Nakabayashi, MD, PhD

Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Office of Medical Informatics and Epidemiology

Osamu Komiyama

What Are Valuable Data for the Clinical Evaluation of Novel Drugs? Industry Pespective

Osamu Komiyama

Pfizer R&D Japan G.K., Japan

Senior Manager, Statistical Research & Data Science

Yoji Nagai, MD, PhD

Perspectives for the Optimization of Data Collection

Yoji Nagai, MD, PhD

Foundation for Biomedical Research & Innovation, Japan

Deputy Director, Translational Research Informatics Center

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.